NUK - logo

Rezultati iskanja

Osnovno iskanje    Ukazno iskanje   

Trenutno NISTE avtorizirani za dostop do e-virov NUK. Za polni dostop se PRIJAVITE.

1 2 3 4 5
zadetkov: 169
1.
  • Smoothened Variants Explain... Smoothened Variants Explain the Majority of Drug Resistance in Basal Cell Carcinoma
    Atwood, Scott X.; Sarin, Kavita Y.; Whitson, Ramon J. ... Cancer cell, 03/2015, Letnik: 27, Številka: 3
    Journal Article
    Recenzirano
    Odprti dostop

    Advanced basal cell carcinomas (BCCs) frequently acquire resistance to Smoothened (SMO) inhibitors through unknown mechanisms. Here we identify SMO mutations in 50% (22 of 44) of resistant BCCs and ...
Celotno besedilo

PDF
2.
  • Efficacy and safety of vism... Efficacy and safety of vismodegib in advanced basal-cell carcinoma
    Sekulic, Aleksandar; Migden, Michael R; Oro, Anthony E ... The New England journal of medicine, 06/2012, Letnik: 366, Številka: 23
    Journal Article
    Recenzirano
    Odprti dostop

    Alterations in hedgehog signaling are implicated in the pathogenesis of basal-cell carcinoma. Although most basal-cell carcinomas are treated surgically, no effective therapy exists for locally ...
Celotno besedilo

PDF
3.
  • Clonal replacement of tumor-specific T cells following PD-1 blockade
    Yost, Kathryn E; Satpathy, Ansuman T; Wells, Daniel K ... Nature medicine, 08/2019, Letnik: 25, Številka: 8
    Journal Article
    Recenzirano
    Odprti dostop

    Immunotherapies that block inhibitory checkpoint receptors on T cells have transformed the clinical care of patients with cancer . However, whether the T cell response to checkpoint blockade relies ...
Celotno besedilo

PDF
4.
  • An Investigator-Initiated O... An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib
    Danial, Christina; Sarin, Kavita Y; Oro, Anthony E ... Clinical cancer research, 03/2016, Letnik: 22, Številka: 6
    Journal Article
    Recenzirano
    Odprti dostop

    To assess the tumor response to the smoothened (SMO) inhibitor, sonidegib (LDE225), in patients with an advanced basal cell carcinoma (BCC) resistant to treatment with vismodegib (GDC0449). Nine ...
Celotno besedilo

PDF
5.
  • Massively parallel single-c... Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion
    Satpathy, Ansuman T; Granja, Jeffrey M; Yost, Kathryn E ... Nature biotechnology, 08/2019, Letnik: 37, Številka: 8
    Journal Article
    Recenzirano
    Odprti dostop

    Understanding complex tissues requires single-cell deconstruction of gene regulation with precision and scale. Here, we assess the performance of a massively parallel droplet-based method for mapping ...
Celotno besedilo

PDF
6.
  • Increased Risk of Cutaneous... Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma
    Mohan, Shalini V; Chang, Julia; Li, Shufeng ... JAMA dermatology (Chicago, Ill.), 05/2016, Letnik: 152, Številka: 5
    Journal Article
    Recenzirano
    Odprti dostop

    Smoothened inhibitors (SIs) are a new type of targeted therapy for advanced basal cell carcinoma (BCC), and their long-term effects, such as increased risk of subsequent malignancy, are still being ...
Celotno besedilo

PDF
7.
  • Characterization of dermati... Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study
    Min Lee, Charles Kyung; Li, Shufeng; Tran, Duy Cong ... Journal of the American Academy of Dermatology, 12/2018, Letnik: 79, Številka: 6
    Journal Article
    Recenzirano
    Odprti dostop

    Cutaneous adverse events are common with programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors. However, the nature of the specific cutaneous adverse event of dermatitis has not been ...
Celotno besedilo

PDF
8.
  • Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell Carcinoma
    Patel, Roma; Chang, Anne Lynn S American journal of clinical dermatology 20, Številka: 4
    Journal Article
    Recenzirano
    Odprti dostop

    Cutaneous squamous cell carcinoma (CSCC) is one of the most common human malignancies, and the incidence is increasing with time. High mutational loads, known infiltration with lymphocytes, and ...
Celotno besedilo
9.
  • Treatment with two differen... Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
    Migden, Michael R, Dr; Guminski, Alexander, PhD; Gutzmer, Ralf, Prof ... The lancet oncology, 06/2015, Letnik: 16, Številka: 6
    Journal Article
    Recenzirano

    Summary Background Patients with advanced basal cell carcinoma have limited treatment options. Hedgehog pathway signalling is aberrantly activated in around 95% of tumours. We assessed the antitumour ...
Celotno besedilo
10.
  • Cemiplimab in locally advan... Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial
    Migden, Michael R; Khushalani, Nikhil I; Chang, Anne Lynn S ... The lancet oncology, 02/2020, Letnik: 21, Številka: 2
    Journal Article
    Recenzirano
    Odprti dostop

    Cemiplimab has shown substantial antitumour activity in patients with metastatic cutaneous squamous cell carcinoma. Patients with locally advanced cutaneous squamous cell carcinoma have poor ...
Celotno besedilo

PDF
1 2 3 4 5
zadetkov: 169

Nalaganje filtrov